Three institutional holders now hold 5%+ passive stakes, indicating strong institutional conviction. Monitor for any 13D conversion or additional stake accumulation by these holders, though all filings currently certify passive intent.
VNDA drugs
VNDA drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1- T+0 · Nov 10 $4.08entry
- T+1 · 6d ago +1.72%α +0.40% · $4.15
- T+4 · todayOpen
- T+5 · in 4h Pending
- T+20 · in 22d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
State Street Corporation filed a Schedule 13G disclosing a 5.0% passive stake in Vanda Pharmaceuticals as of September 30, 2026, with 3,010,531 shares held. This is a new filing by State Street, adding to existing institutional interest from BlackRock (5.9%) and Millennium Management (7.0%). The passive filing indicates no activist intent, but the presence of three large asset managers with 5%+ stakes signals notable institutional conviction in the company.
Key Financial Metrics
Key Facts
- State Street Corp filed a new Schedule 13G disclosing a 5.0% passive stake in Vanda Pharmaceuticals
- State Street holds 3,010,531 shares as of September 30, 2026
- The filing certifies passive intent under Rule 13d-1(b), with no control or influence purpose
- State Street joins BlackRock (5.9%) and Millennium Management (7.0%) as 5%+ holders
- Vanda reported Q3 2026 revenue of $69.8M (+24% YoY) and narrowed net loss, beating consensus
Financial Impact
State Street's stake of 3,010,531 shares represents 5.0% of Vanda's outstanding shares, valued at approximately $11.6M based on the $231M market cap
Risk Factors
- No activist intent disclosed, but large passive stakes could be sold without notice
- High institutional concentration (BlackRock, Millennium, State Street) may amplify selling pressure if sentiment shifts
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13G Filing (Primary) | 0000093751-26-000739 |
| Document: 0000093751-26-000739-index.html | 0000093751-26-000739 |
| Document: 0000093751-26-000739.txt | 0000093751-26-000739 |
Track record
8 reports on VNDA
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $3.99 Now $3.81 −4.51% settles Nov 20
- Nov 10, 20266d ago SC 13G Neutral 3/10 Viewing Entry $4.08 Now $3.81 −6.62% settles Nov 17
- Oct 28, 202619d ago 8-K Bullish 6/10 Entry $4.05 to $3.59 Now $3.81 −5.93% ▼ −11.36% −6.63% vs SPY
- Oct 27, 202620d ago SC 13G Neutral 4/10 Entry $4.00 to $3.88 Now $3.81 −4.75% ▼ −3.00% −2.29% vs SPY
- Oct 21, 202626d ago Press Release Neutral 1/10 Entry $4.05 to $4.05 Now $3.81 −5.93% · 0.00% −0.71% vs SPY
- Oct 9, 20265w ago SC 13G/A Neutral 4/10 Entry $4.54 to $4.09 Now $3.81 −16.08% ▼ −9.91% −8.42% vs SPY
- Jul 29, 202615w ago Press Release Neutral 1/10 Entry $5.18 Now $3.81 −26.45% No price data
- May 6, 202627w ago 8-K Mixed 6/10 Entry $6.39 to $6.43 Now $3.81 −40.38% ▲ +0.63% −0.88% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers